Lung stem cells have a hidden self-repair switch they activate after injury
After damage, lung stem cells produce their own molecular signal that tells them when to start regenerating.
The lung is one of the hardest organs in the body to repair. Unlike the liver or skin, which can restore damaged tissue relatively quickly, the lungs respond to injury slowly and unreliably. In diseases like idiopathic pulmonary fibrosis — a condition in which healthy lung tissue is progressively replaced by scar tissue — that repair capacity fails almost entirely. Effective treatments remain scarce.
A new study published in Science identifies an unexpected mechanism by which lung stem cells regulate their own activity. Researchers found that a specific type of lung stem cell — known as basal stem cells — produces a complex consisting of the protein IGF (Insulin-like Growth Factor) and an associated binding protein after injury. This complex acts as an autocrine signal: the cell makes it and also responds to it. The signal instructs the stem cell when it is time to divide and generate new tissue.
Autocrine: the cell giving itself orders
Autocrine signaling — where a cell secretes a molecule that acts back on itself — was already known in other biological contexts, but this particular mechanism in lung stem cells had not been described before. What makes it distinctive is the combination: not the IGF protein alone, but the full complex with its binding protein turns out to be the critical activator. The binding protein governs where, when, and for how long the IGF signal remains active — a detail that is biologically far from trivial.
In healthy lung tissue, this circuit produces a controlled response to damage. In fibrosis and other lung diseases, the circuit appears to malfunction — either by becoming too inactive, so that repair stalls, or by becoming overactive and contributing to excessive cell growth. The study does not yet provide a complete picture of how it goes wrong, but it identifies a concrete molecular target for future investigation.
From mouse lung to human treatment
The findings are based primarily on mouse models and human cell cultures. The translation to clinical therapies is a long road. But the underlying biology is plausible — the IGF system is well studied in humans, even if its tissue-specific effects are complex and sometimes contradictory.
For aging science, this is relevant because lung function is one of the strongest predictors of life expectancy. Maximum lung capacity begins declining gradually from around age thirty. Whether this autocrine stem cell circuit plays a role in that long-term decline — and whether it could be targeted to preserve lung function longer — is now a question the field has the tools to start answering.